Document 0961
 DOCN  M9440961
 TI    Noncytotoxic approaches to the treatment of HIV-associated Kaposi's
       sarcoma.
 DT    9404
 AU    Pluda JM; Parkinson DR; Feigal E; Yarchoan R; Investigational Drug
       Branch, CTEP/DCT/NCI, Rockville, MD 20852.
 SO    Oncology (Huntingt). 1993 Dec;7(12):25-33; discussion 33, 37-8. Unique
       Identifier : AIDSLINE MED/94122077
 AB    Kaposi's sarcoma (KS) is an otherwise unusual disease that frequently
       complicates the course of HIV infection. While there is some evidence to
       suggest that the pathogenesis of KS is driven by a variety of cytokines
       and cellular factors, the exact pathogenesis of the disease is unknown
       at present. Current therapy for HIV-associated KS has been developed
       empirically and involves, for the most part, classic cytotoxic
       chemotherapy. However, as more is learned about the pathogenesis of KS
       lesions, new and novel therapeutic modalities may emerge aimed at
       interrupting or blocking the activity of the pathogenetic factors
       involved.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS  Combined Modality
       Therapy  Female  Human  HIV Infections/*COMPLICATIONS  Male  Sarcoma,
       Kaposi's/*DRUG THERAPY/ETIOLOGY/THERAPY  Sex Distribution  JOURNAL
       ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).